Neumora Therapeutics, Inc. Common StockNMRANASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-182.94M
↓ 62% below average
Average (4y)
$-113.21M
Historical baseline
Range
High:$-28.06M
Low:$-182.94M
CAGR
+59.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-182.94M | -12.0% |
| 2023 | $-163.40M | -41.6% |
| 2022 | $-115.41M | -51.4% |
| 2021 | $-76.24M | -171.7% |
| 2020 | $-28.06M | - |